Biokangtai

What Biokangtai does

Biokangtai (Shenzhen Kangtai Biological Products Co., Ltd.; Shenzhen Stock Exchange ChiNext: 300601) is a Chinese vaccine developer and manufacturer founded in 1992, headquartered in Shenzhen with major R&D and production operations in Beijing through its wholly-owned subsidiary Beijing Minhai Biotechnology, acquired in 2008. The company commercializes a portfolio of 11 approved human vaccines plus 2 emergency use authorizations spanning pediatric and adult immunization, including the globally first dual-carrier 13-valent pneumococcal polysaccharide conjugate vaccine, the globally first 60μg hepatitis B vaccine, the domestically first human diploid cell rabies vaccine, the domestically first DTaP-Hib four-in-one combined vaccine, and vaccines against varicella, hepatitis B, Hib, MMR, Sabin polio, 23-valent pneumococcal disease, and COVID-19. Its technology stack spans multiple vaccine platforms including viral attenuated, viral inactivated, gene engineering, bacterial polysaccharide, polysaccharide-protein conjugation, combined, viral vector, mRNA, and novel adjuvant platforms, supported by over 90 patents and an in-registration pipeline of 18 projects plus near 30 R&D programs targeting five-in-one and six-in-one combined vaccines, RSV, and novel superbug indications.

The company makes money through three distinct revenue streams: domestic B2B sales of vaccine products through a distribution network covering all 31 Chinese provinces for government immunization programs and private market vaccination; finished vaccine product exports to 20+ countries across Southeast Asia, South Asia, Middle East, Africa, Latin America, and Central Asia; and bulk antigen/semi-finished product exports plus full technology transfer agreements enabling local manufacturing by overseas partners. International customers include government health authorities, GAVI/UNICEF-aligned procurement channels, and licensed pharmaceutical distributors. In March 2025, Biokangtai established a 50/50 joint venture with AstraZeneca valued at USD 400 million total investment for global innovative vaccine R&D and manufacturing for China and emerging markets.

Name

Biokangtai

Legal name

深圳康泰生物制品股份有限公司

Website

https://biokangtai.com

Company type

Public

Founded year

1992

Operating status

Operating

Headcount range

1–10 employees

Short description

Biokangtai is a Shenzhen-listed Chinese vaccine developer and manufacturer selling 11 approved pediatric and adult human vaccines, including the globally first dual-carrier PCV13 and 60μg hepatitis B vaccine, to government immunization programs, hospitals, and international pharmaceutical partners across 20+ countries.

Ownership category

akta.pro rank

Product category

Human Vaccines

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro industry

PRIMARYHLAIAEAM

Vaccine Clinical Development & Regulatory Affairs

Healthcare & Life Sciences/Pharmaceuticals/Vaccines

SECONDARYHLAIAJAG

Vaccines & Cold-Chain Pharmaceutical Distributors

Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling

SECONDARYHLAAAEAK

Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release)

Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

SECONDARYHLAIAEAE

Travel & Tropical Disease Vaccines

Healthcare & Life Sciences/Pharmaceuticals/Vaccines

Keywords

• Human vaccines
• Pneumococcal conjugate vaccines
• Hepatitis B vaccines
• Combined vaccines
• Vaccine manufacturing

Headquarters

HQ city

Guangdong

HQ country

China

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Vaccine Product Sales - Domestic China: Sale of vaccine products including children's vaccines (13-valent PCV, DTaP-Hib, hepatitis B, varicella, Hib, MMR, polio) and adult vaccines (hepatitis B, rabies, 23-valent PPV, varicella, COVID-19) through domestic distribution network covering 31 provinces
2. Vaccine Product Exports: Finished vaccine product exports registered and sold in overseas markets including Southeast Asia, South Asia, Middle East, Africa, Latin America
3. Bulk Antigen/Bulk Drug Substance Exports: Semi-finished product exports where overseas partners perform local filling and packaging
4. Technology Transfer: Technology transfer services enabling overseas partners to conduct local manufacturing, including full technology transfer for local production and registration support

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Shenzhen Kangtai Biological Products Co., Ltd. (Biokangtai) is a Chinese biopharmaceutical company that researches, develops, manufactures, and sells human vaccines. Its portfolio includes children's vaccines (13-valent pneumococcal polysaccharide conjugate vaccine, DTaP-Hib four-in-one, hepatitis B, varicella, Hib, MMR, Sabin polio) and adult vaccines (hepatitis B 20µg/60µg, human diploid cell rabies, 23-valent pneumococcal, COVID-19 inactivated and adenovirus vector). The company operates five R&D and production bases in Shenzhen and Beijing and sells domestically through a network covering all 31 Chinese provinces plus international markets across 20+ countries.

Differentiator

Problem solved

Functional benefit

Products and services

• 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Dual-carrier 13-valent pneumococcal polysaccharide conjugate vaccine for infants and young children preventing pneumococcal disease; world's first product of its kind with six invention patents.
• Recombinant Hepatitis B Vaccine (Saccharomyces cerevisiae) — 60µg Globally first innovative 60 microgram hepatitis B vaccine for adult immunization, targeting patients with chronic hepatitis B; only product of its kind worldwide.
• Recombinant Hepatitis B Vaccine (10µg / 20µg) Recombinant hepatitis B vaccine in 10µg (infant) and 20µg (adult) dosages produced in Saccharomyces cerevisiae, preventing hepatitis B infection across age groups.
• DTaP-Hib Combined Vaccine (Four-in-one) Acellular DTaP-Hib four-in-one combination vaccine for infants, simultaneously preventing diphtheria, tetanus, pertussis, and Haemophilus influenzae type b; first domestically developed tetravalent vaccine.
• 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) 23-valent pneumococcal polysaccharide vaccine for adults and elderly, protecting against pneumococcal disease caused by 23 serotypes.
• Lyophilized Human Diploid Cell Rabies Vaccine Lyophilized rabies vaccine produced in human diploid cells for post-exposure prophylaxis; first domestic approved vaccine offering the 2-1-1 four-dose immunization schedule.
• Varicella Live Attenuated Vaccine Live attenuated varicella vaccine for preventing chickenpox, applicable to both children and adults; the world's first to apply an external ultrasonic disruption cell factory virus harvesting method.
• COVID-19 Inactivated Vaccine (Vero cells) Inactivated COVID-19 vaccine produced in Vero cells, used for adult immunization against SARS-CoV-2; received emergency use authorization.
• Recombinant COVID-19 Vaccine (Y25 Adenovirus Vector) Adenovirus vector-based recombinant COVID-19 vaccine, licensed from AstraZeneca, manufactured and commercialized in mainland China, Pakistan, and Indonesia.
• Sabin-strain Inactivated Poliovirus Vaccine (Vero cells) Inactivated poliovirus vaccine based on Sabin strain, manufactured in Vero cells, used for pediatric polio immunization.
• Hib Conjugate Vaccine (Lyophilized) Lyophilized Haemophilus influenzae type b (Hib) conjugate vaccine for pediatric immunization against bacterial meningitis and related infections.
• Measles-Rubella Combined Live Attenuated Vaccine Combined measles-rubella live attenuated vaccine for pediatric immunization against measles and rubella.
• Acellular DTaP Combined Vaccine Acellular diphtheria-tetanus-pertussis (DTaP) combined vaccine for pediatric immunization.

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Partnerships

17 partnerships are on record, tiered core, major and minor.

• DCVMN (Developing Countries Vaccine Manufacturers Network)coreStrategic or Co-development Partner · 1 November 2025BioKangtai is a member of DCVMN, an international organization with 115+ cooperation agreements among members including 41 South-South cooperation projects. CEO Dr. Rajinder Suri visited Minhai Bio to explore collaboration opportunities.
• AstraZenecacoreStrategic or Co-development Partner · 21 March 2025AstraZeneca and BioKangtai established a joint venture company in Beijing Economic and Technological Development Zone with registered capital of 345 million USD (4 billion USD total investment), each holding 50% equity. The joint venture will be AstraZeneca's first and only vaccine manufacturing base in China, focusing on R&D and production of global innovative vaccines for China and emerging markets.
• Ethiopia Ministry of HealthmajorStrategic or Co-development Partner · 1 March 2025Ethiopia Health Ministry representatives visited Minhai Bio to discuss vaccine technology transfer cooperation, including measles, diphtheria-tetanus, rabies, and PCV13 vaccines.
• Ghana Vaccine CompanymajorChannel Partner/ Reseller/ Distributor · 1 January 2025Minhai Bio signed agreement with Ghana vaccine enterprise for dual-carrier PCV13 bulk drug substance license, supply and technology transfer. Partner plans to cover West and Central Africa markets and GAVI/UNICEF.
• Phil. Pharmawealth Inc. (Philippines)majorChannel Partner/ Reseller/ Distributor · 1 January 2025Licensing and agency agreement with Philippines' largest injection drug importer for 13-valent and 23-valent pneumococcal vaccines registration, promotion, and sales.
• Biotis (Indonesia)majorChannel Partner/ Reseller/ Distributor · 1 January 2025Partnership with Indonesian Biotis company for technology transfer of world's first dual-carrier PCV13, Indonesia's first vaccine technology transfer project from China that achieved local manufacturing and market approval.
• Bangladesh Pharmaceutical CompanymajorChannel Partner/ Reseller/ Distributor · 1 January 2025Partnership with Bangladesh company for authorization agency and technology transfer of PCV13 bulk drug substance for local registration, listing, and distribution in Bangladesh.
• Turkish Ministry of Health and Vaccine CompaniesmajorStrategic or Co-development Partner · 1 January 2025Turkish Deputy Minister of Health and delegation visited BioKangtai Minhai Bio, reaching comprehensive cooperation intentions in vaccine R&D, clinical trials, manufacturing, and local distribution.
• Chinese Academy of Sciences Institute of MicrobiologycoreStrategic or Co-development Partner · 1 January 2024Co-founded 'Synthetic Immunology and Vaccine Intelligent Manufacturing Beijing Key Laboratory' with Minhai Bio,馨智生物, and Chengda Tianhe. Laboratory focuses on AI-assisted antigen design, variant monitoring, and rapid vaccine response systems.
• Gennvax (Egypt)majorStrategic or Co-development Partner · 1 August 2023Minhai Bio signed technology transfer agreement with Egyptian company Gennvax for PCV13 and DTaP-Hib-sIPV five-in-one combination vaccines, supporting Egypt Vaccine Manufacturers Alliance (EVMA) goal of 50% vaccine localization by 2030.
• Combiphar (Indonesia)majorChannel Partner/ Reseller/ Distributor · 1 March 2023Partnership with Combiphar for vaccine cooperation signed at Boao Forum, advancing PCV13 market access in Indonesia.
• DESMONS CONSULTING SPRL (Belgium)minorStrategic or Co-development Partner · 1 July 2021Framework agreement for vaccine project cooperation with Belgian consulting company DESMONS for European market development.
• AMSISA/Universidad de ChileminorStrategic or Co-development Partner · 1 May 2021Cooperation agreement signed with Universidad de Chile for vaccine project collaboration in Latin America.
• AstraZeneca (英国阿斯利康)coreStrategic or Co-development Partner · 1 January 2020BioKangtai holds license to manufacture and commercialize AstraZeneca's recombinant COVID-19 vaccine (adenovirus vector) in mainland China, Pakistan, and Indonesia. The company serves as AstraZeneca's exclusive COVID-19 vaccine partner in China.
• Sanofi Pasteur (法国赛诺菲巴斯德)coreStrategic or Co-development Partner · 1 January 2014Technology transfer and cooperation with Sanofi Pasteur for rabies vaccine technology in 2014, part of BioKangtai's strategy to acquire advanced international vaccine technologies.
• Intravacc (荷兰)coreStrategic or Co-development Partner · 1 January 2014Technology transfer cooperation with Dutch Intravacc for poliomyelitis vaccine technology in 2014, enhancing BioKangtai's polio vaccine development capabilities.
• Merck (美国默克公司)coreStrategic or Co-development Partner · 1 January 1992BioKangtai undertook gene recombination hepatitis B vaccine technology introduction and production from US-based Merck in 1992, marking the company's founding mission and establishing long-term technology cooperation relationship.

Scale indicators7 records

Recent moves13 records

Expansion highlights6 records

Broad incumbents

• Merck & Co., Inc. One of the 'big four' vaccine majors (with Sanofi, GSK, Pfizer) and Biokangtai's original technology partner since 1992 for gene-recombination hepatitis B; a global incumbent across the same pediatric/adult vaccine categories.
• Sanofi Pasteur: Global top vaccine manufacturer and one of Biokangtai's core strategic partners (technology transfer for rabies vaccine in 2014); not a direct competitor in China but a developer of competing global vaccines.
• Pfizer Inc. Global vaccine major with the established multi-billion-dollar PCV13 franchise (Prevnar 13) that Biokangtai's dual-carrier PCV13 directly targets; key competitor in pediatric pneumococcal vaccination globally.
• GSK plc: Global vaccine major with leading pneumococcal, hepatitis, and combination vaccine franchises (e.g., PCV10, Infanrix); competes with Biokangtai across both pediatric and adult vaccine categories globally.

Direct peers

• Walvax Biotechnology Co., Ltd. Leading privately-held Chinese vaccine manufacturer with broad human vaccine portfolio including the pioneering domestic 13-valent pneumococcal conjugate vaccine ('Wei Menci') competitor to Biokangtai's product, making it the closest direct Chinese peer across vaccine R&D, manufacturing, and domestic distribution.
• Bharat Biotech: Indian vaccine innovator with strengths in combined vaccines, rotavirus, and infectious-disease biologics; comparable to Biokangtai in target markets (emerging-market pediatric immunization) and in technology platform depth.
• Sinopharm (China National Biotec Group): State-owned Chinese vaccine leader under Sinopharm producing hepatitis B, polio, influenza, rabies and other vaccines across multiple subsidiaries; competes with Biokangtai in the same domestic vaccine categories and shares the immunization program distribution channel.
• Serum Institute of India (SII): World's largest vaccine manufacturer by dose volume and the principal emerging-market exporter of low-cost PCV13, DTP, HPV and other vaccines; competes directly with Biokangtai in GAVI/UNICEF supply contracts and emerging-market national immunization tenders.
• Hualan Biological Engineering Inc. Listed Chinese vaccine manufacturer and blood products company that competes with Biokangtai in influenza, hepatitis B, and other human vaccines, with overlapping domestic distribution and public immunization program focus.
• Zhifei Biological Products Inc. Major Chinese vaccine distributor and manufacturer (300122.SZ) with strong ties to Merck HPV and other vaccines; competes with Biokangtai in Chinese pediatric and adult vaccine markets and provides an apples-to-apples comparator for distribution scale and margin profile.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/biokangtai
• YouTubeyoutube.com/@BioKangtai
• Facebookfacebook.com/biokangtaiglobal
• LinkedInlinkedin.com/company/shenzhen-kangtai-biological-products-co-ltd-

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biokangtai